Skip to main content
Image placeholder title

Zejula (Niraparib) Improves Progression-Free Survival in Ovarian Cancer

The PARP inhibitor Zejula is a precision cancer medicine that delays ovarian cancer progression and prolongs survival.

Mirvetuximab Soravtansine

The Antibody Drug Conjugate Mirvetuximab soravtansine appears promising for treatment of certain patients with ovarian cancer.

The Antibody Drug Conjugate Mirvetuximab soravtansine appears promising for treatment of certain patients with ovarian cancer.

Image placeholder title

Lynparza Delays Progression & Significantly Prolongs Survival in Ovarian Cancer

5 Year follow up data - Lynparza maintenance therapy effective for women with BRCA + and other mutated ovarian cancers.

Ovarian Cancer Connect is a unique resource that brings patients, caregivers, advocates and experts together in a single community where individuals benefit from a blend of expert-authored news and educational programming alongside a robust social network, providing insight into symptoms, diagnosis, treatment, and the support of other individuals being treated at some of the best cancer centers. Ovarian Cancer Connect offers users expert authored clinically-reviewed information and the perspective of their peers in a safe, objective space, helping to ensure they become empowered in their healthcare journey.